Principal Financial Group Inc. Reduces Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Principal Financial Group Inc. trimmed its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 25.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 10,608 shares of the biopharmaceutical company’s stock after selling 3,581 shares during the quarter. Principal Financial Group Inc.’s holdings in Alnylam Pharmaceuticals were worth $2,918,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of ALNY. Souders Financial Advisors increased its position in shares of Alnylam Pharmaceuticals by 1.0% in the second quarter. Souders Financial Advisors now owns 3,512 shares of the biopharmaceutical company’s stock valued at $853,000 after buying an additional 36 shares in the last quarter. V Square Quantitative Management LLC increased its holdings in Alnylam Pharmaceuticals by 21.9% in the 2nd quarter. V Square Quantitative Management LLC now owns 334 shares of the biopharmaceutical company’s stock worth $81,000 after acquiring an additional 60 shares in the last quarter. Allspring Global Investments Holdings LLC raised its position in Alnylam Pharmaceuticals by 54.2% during the second quarter. Allspring Global Investments Holdings LLC now owns 259 shares of the biopharmaceutical company’s stock worth $63,000 after acquiring an additional 91 shares during the period. Farther Finance Advisors LLC lifted its holdings in Alnylam Pharmaceuticals by 95.4% during the third quarter. Farther Finance Advisors LLC now owns 211 shares of the biopharmaceutical company’s stock valued at $58,000 after purchasing an additional 103 shares in the last quarter. Finally, Ashton Thomas Private Wealth LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the second quarter valued at about $26,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on ALNY. Bank of America raised their price target on shares of Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the company a “buy” rating in a research note on Monday, October 14th. Royal Bank of Canada reiterated an “outperform” rating and set a $300.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, November 1st. Citigroup raised their price objective on Alnylam Pharmaceuticals from $291.00 to $342.00 and gave the company a “buy” rating in a report on Friday, August 2nd. TD Cowen upped their target price on shares of Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the stock a “buy” rating in a report on Monday, October 21st. Finally, JPMorgan Chase & Co. raised their price target on shares of Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the stock a “neutral” rating in a research note on Monday, August 26th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and nineteen have given a buy rating to the stock. According to MarketBeat.com, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $298.09.

Alnylam Pharmaceuticals Stock Down 0.8 %

Shares of NASDAQ ALNY opened at $244.89 on Friday. Alnylam Pharmaceuticals, Inc. has a 52-week low of $141.98 and a 52-week high of $304.39. The business’s 50 day moving average is $273.54 and its two-hundred day moving average is $236.84. The firm has a market cap of $31.59 billion, a price-to-earnings ratio of -93.35 and a beta of 0.39. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 31.64.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The firm had revenue of $500.90 million for the quarter, compared to analyst estimates of $532.91 million. The business’s revenue for the quarter was down 33.3% on a year-over-year basis. During the same period last year, the firm posted $1.15 earnings per share. Research analysts predict that Alnylam Pharmaceuticals, Inc. will post -2.22 EPS for the current year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.